InMode’s products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share ...

Below I explain why InMode has sold off so aggressively since the start of 2022. With $400M of cash on hand, management could repurchase 25% of their float based on InMode's current valuation. NTM ...

On September 9, 2025, DOMA Perpetual Capital Management LLC announced it had sent a letter to InMode Ltd.'s Board urging approval of a 10% share buyback in Q4 2025 and another 10% in Q1 2026, while ...

To the Board Members of InMode: InMode's valuation has continued to contract. We believe this is partly due to management's chaotic leadership; one reason sales remain low is the detrimental decision ...

There were two different stories for InMode (NASDAQ: INMD) in 2022. In the first half of the year, the medical device stock plunged 68%. However, in the second half, InMode roared back, with its ...

To the Board Members of InMode: DOMA Perpetual Capital Management is an asset manager focused on generating long-term value for its investors. DOMA is one of the largest shareholders of InMode (the ...

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of InMode Ltd. (NASDAQ: INMD) common stock between June 4, 2021 and October 12, 2023, inclusive ...